Skip to main content
Fig. 4 | EJNMMI Research

Fig. 4

From: Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation

Fig. 4

a Uptake of [111In-DOTA]MG11 in kidneys and A431-CCK2R(+) and A431-CCK2R(−) tumors at 4 h pi in SCID mice for controls and increasing amounts of the NEP inhibitors TO and PA. Data are given as mean of %ID/g ± SD, n ≥ 4. [111In-DOTA]MG11 iv-coinjection with vehicle (), with 1.5 μg TO (), with 15 μg TO (), with 150 μg TO (), with 3 μg PA (), with 30 μg PA (), or 300 μg PA () in SCID mice bearing twin A431-CCK2R(+) (Tu+) and naïve A431-CCK2R(−) (Tu−) human xenografts. b Corresponding tumor-to-kidney ratios (Tu/Ki)

Back to article page